Warsaw

• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• A study to learn how bimekizumab works in people with moderate to severe plaque psoriasis. Ended recruitment
  2023-506333-29-00 11 2024-10-01 Moderate to Severe Plaque Psoriasis
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• Ph2 Study of MK-3475A in Hematologic Malignances in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refra … Ended recruitment
  2024-510969-42-00 4 2024-09-30 Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapse
• A study to check the effect of satralizumab in children and adolescents living with Duchenne muscular dystrophy, to check if it is safe and … Ended recruitment
  2024-512383-65-00 4 2024-09-26 Duchenne Muscular Dystrophy (DMD)
• A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended recruitment
  2023-503692-24-00 5 2024-09-25 Cutaneous Lupus Erythematosus
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No … Ended recruitment
  2023-510279-80-00 4 2024-09-25 Prurigo nodularis
• PROSPER: clinical Phase 2 study to test how safe and effective is a new medicine called FNP-223 to slow disease progression of progressive s … Ended recruitment
  2023-510366-28-00 4 2024-09-25 Progressive supranuclear palsy (PSP)
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: A Randomize … Ended recruitment
  2023-507527-28-00 7 2024-09-16 Recurrent vulvovaginal candidiasis
• A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended recruitment
  2023-506769-67-00 4 2024-09-04 Moderate to Severely Active Ulcerative Colitis
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu … Ended recruitment
  2024-510965-41-00 5 2024-09-03 Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
• A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended recruitment
  2024-511260-84-00 4 2024-09-03 Atopic Dermatitis
• A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) Ended recruitment
  2022-501452-29-00 9 2024-08-28 Metastatic Non-small Cell Lung Cancer
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive … Ended recruitment
  2024-510908-37-00 5 2024-08-28 KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
• MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper … Ended recruitment
  2023-508670-28-00 5 2024-08-26 Hypertension
• A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended recruitment
  2023-505423-31-00 5 2024-08-08 advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
• Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Ended recruitment
  2023-504331-41-00 5 2024-08-02 Respiratory tract diseases - Wheezing, Asthma
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu … Ended recruitment
  2023-509762-38-00 5 2024-08-01 Respiratory Syncytial Virus Infections
• Phase 2 Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma Ended recruitment
  2023-505177-32-00 4 2024-07-31 Intermediate-high -risk RCC, high-risk RCC who have undergone nephrect
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended recruitment
  2023-507204-31-00 5 2024-07-26 Hidradenitis Suppurativa

Showing 889–912 of 1,708 trials